Ethos Capital Management Inc. Buys Shares of 6,273 AbbVie Inc. $ABBV

Key Points

• Ethos Capital Management bought a new stake of 6,273 AbbVie shares in Q4, valued at about $1.433 million according to its latest 13F filing.
• AbbVie lowered Q1 and FY‑2026 guidance after taking a $744M R&D charge and agreed to list Humira on TrumpRx at roughly an 86% discount, raising near‑term revenue risk and helping drive a ~12% share pullback over the past month.
• Analysts carry an average "Moderate Buy" rating with a consensus price target of $253.15; insiders have recently sold shares (EVP Perry Siatis sold 22,381), institutions own ~70.2% of the stock, and AbbVie pays a $1.73 quarterly dividend (3.4% yield).

Ethos Capital Management Inc. bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,273 shares of the company's stock, valued at approximately $1,433,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock valued at $3,056,000 after buying an additional 789 shares in the last quarter. Gamco Investors INC. ET AL grew its stake in shares of AbbVie by 18.0% in the second quarter. Gamco Investors INC. ET AL now owns 15,750 shares of the company's stock valued at $2,923,000 after buying an additional 2,402 shares in the last quarter. Finally, Transce3nd LLC grew its stake in shares of AbbVie by 46.1% in the second quarter. Transce3nd LLC now owns 434 shares of the company's stock valued at $81,000 after buying an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: JPMorgan calls the recent pullback a buying opportunity and reiterates confidence with a $260 price target, arguing valuation and long‑term cash flow from immunology and aesthetics create upside for ABBV. AbbVie Gets JPMorgan Buying Opportunity Call
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) opened a new AMI training center in Austin, strengthening commercial support and physician training for aesthetics products — a gradual, supportive tailwind for the aesthetics portfolio. Allergan Aesthetics Third AMI Center Opens
• Neutral Sentiment: AbbVie updated an ongoing real‑world Parkinson’s observational study in Belgium — progress on neurology evidence can support longer‑term pipeline value, but this is an informational update without immediate commercial impact. AbbVie’s Real‑World Parkinson’s Study
• Neutral Sentiment: Analyst coverage is mixed but constructive: the stock retains an average "Moderate Buy" rating, and several articles revisit valuation, dividend yield and upcoming Q1 earnings (April 29) as key decision points for investors. These views temper panic but don’t change fundamentals immediately. Analyst Average Rating
• Negative Sentiment: AbbVie agreed to list Humira on the TrumpRx discount program at an ~86% discount under a White House pricing pact — this is a major pricing concession for a legacy blockbuster and increases near‑term revenue risk and valuation uncertainty for the post‑exclusivity Humira franchise. AbbVie Puts Humira on TrumpRx
• Negative Sentiment: AbbVie lowered its Q1 and FY‑2026 outlook after taking a $744M R&D charge — the guide cut and one‑time charge weigh on near‑term EPS trajectory and help explain recent share weakness. AbbVie Lowers Q1 and FY‑2026 Outlook
• Negative Sentiment: Market commentary and headlines note ABBV underperformed peers and shares have pulled back ~12% over the past month — amplifying investor sensitivity to guidance, Humira pricing moves, and upcoming earnings. AbbVie Stock Drops Despite Market Gains

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised AbbVie from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 28th. Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price objective for the company. Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th. Finally, Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and a consensus price target of $253.15.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company's stock.

AbbVie Price Performance

ABBV opened at $206.21 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $364.61 billion, a price-to-earnings ratio of 87.38, a PEG ratio of 0.73 and a beta of 0.38. The business has a fifty day moving average price of $220.95 and a 200 day moving average price of $224.28.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. During the same period in the previous year, the firm posted $2.16 EPS. AbbVie's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's payout ratio is presently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.